Table 2.

Window of opportunity clinical trials utilizing RPPA to identify adaptive responses in on-treatment patient samples

Clinical trial	Investigational agent(s)	Phase	Status	Conclusions
POSITION: Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02316834)	Talazoparib	Early Phase 1	Completed	Patients treated with PARPi monotherapy display individual-specific adaptive responses, with limited interlesional heterogeneity within each patient. PARPi increased RAS/MAPK signaling, PI3K signaling, and activation of S phase and G2/M checkpoint, leading to PARPi trials described in Table 1.
Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02659241)	Adavosertib	Early Phase 1	Recruiting	Ongoing
Targeted PARP or MEK/ERK Inhibition in Patients With Pancreatic Cancer (NCT04005690)	Olaparib and cobimetinib	Early Phase 1	Recruiting	Ongoing